The addition of olanzapine to valproate or lithium for acute manic or mixed bipolar episodes reduced manic symptoms


QUESTION: In patients with acute manic or mixed bipolar episodes, is a combination of olanzapine with valproate or lithium more effective than valproate or lithium alone?

Design
6 week randomised [allocation concealed]*,†, blinded [patients, clinicians, data collectors, and outcome assessors]‡, placebo controlled trial.

Setting
33 centres in the US and 5 in Canada.

Patients
344 patients (mean age 41 y, 52% women) who had bipolar disorder, manic (48%) or mixed (52%) episodes with or without psychotic episodes; had a score ≥16 (mean score 22) on the Young Mania Rating Scale (YMRS) at baseline; and had received treatment with a therapeutic blood concentration of lithium (0.6–1.2 mmol/l) or valproate (50–125 g/ml) for ≥2 weeks before visit 1. Follow up was 97%.

Intervention
Patients were allocated (2:1) to olanzapine, 5, 10, 15, or 20 mg/day (n=334) or placebo (n=110). All patients received valproate or lithium. Adjunctive use of benzodiazepine (≤2 mg/d of lorazepam equivalents) was permitted for ≤14 days cumulatively. Anticholinergic therapy (benztropine mesylate, ≤2 mg/d) could be used for extrapyramidal symptoms but not for prophylaxis.

Main outcome measures
Severity of manic symptoms (YMRS score), clinical response (improvement of ≥50% in YMRS score), and adverse events.

Main results
Analysis was by intention to treat. Patients in the olanzapine combination group had a greater mean decrease in YMRS score than patients in the control group (table). More patients in the olanzapine combination group than in the control group had a clinical response. Olanzapine combination therapy led to increased weight gain, somnolence, tremor, dry mouth, and speech disorder (table). The groups did not differ for dropouts (table).

Conclusion
In patients with acute manic or mixed bipolar episodes, the addition of olanzapine to valproate or lithium reduced manic symptoms but increased some adverse events.

*See glossary.
†Information provided by author.
‡YMRS—Young Mania Rating Scale. Other abbreviations defined in glossary; mean difference, RBI, NNT, RRI, NNH, and CI calculated from data in article.

Olanzapine v placebo in addition to valproate or lithium for manic or mixed episode:

<table>
<thead>
<tr>
<th>Outcomes at 6 weeks</th>
<th>Olanzapine</th>
<th>Placebo</th>
<th>Mean difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean decrease from baseline YMRS score</td>
<td>13.1</td>
<td>9.1</td>
<td>4.0 (2.0 to 6.0)</td>
</tr>
<tr>
<td>≥50% improvement on YMRS</td>
<td>68%</td>
<td>45%</td>
<td>51% (23 to 92)</td>
</tr>
<tr>
<td>Weight gain</td>
<td>26%</td>
<td>7.0%</td>
<td>277% (92 to 658)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>52%</td>
<td>27%</td>
<td>105% (40 to 168)</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>32%</td>
<td>7.8%</td>
<td>277% (118 to 664)</td>
</tr>
<tr>
<td>Tremor</td>
<td>23%</td>
<td>13%</td>
<td>51% (6.6 to 202)</td>
</tr>
<tr>
<td>Speech disorder</td>
<td>6.6%</td>
<td>0.87%</td>
<td>277% (31 to 4348)</td>
</tr>
<tr>
<td>Weight gain</td>
<td>30%</td>
<td>29%</td>
<td>4.0% (−25 to 50)</td>
</tr>
</tbody>
</table>

RBI (CI); NNT (CI); RRI (CI); NNH (CI).

COMMENTARY

Tohen et al have shown that olanzapine is an effective treatment for mania. Based on the effect size of 0.47, the primary measure of manic symptom reduction indicated that 68% (95% CI 59% to 76%) of patients receiving placebo and lithium or valproate improved less than the average patient receiving olanzapine and lithium or valproate. Patients with mixed and pure mania responded similarly to olanzapine augmentation, but the advantage of olanzapine was not statistically significant in patients with pure mania. It is unclear whether olanzapine augmentation should therefore be reserved for mixed episodes or whether the benefit in pure mania is also clinically important and this analysis merely failed to identify this benefit because of low statistical power. Other antidepressants have been shown to be effective for acute mania and are used commonly.1 As such, the next logical question is which antipsychotic is preferred for acute mania. Although this was an acute treatment trial, antipsychotic treatment often continues for months. As a result, when selecting a treatment for acute mania, clinicians need to consider its effectiveness, safety, and tolerability during maintenance treatment. These issues evoke the debate between newer and older antipsychotics but in a completely different patient population. Long term use of older agents commonly leads to motor side effects in bipolar patients, although weight gain can be substantial with some newer agents. This may be particularly relevant in bipolar disorder because lithium and valproate also cause weight gain.2 In this study, olanzapine was associated with a considerable increase in weight relative to placebo (3.1 ± 0.23 kg). Weight gain would be expected to increase with longer use. Clinicians making decisions about whether to use olanzapine or an alternative antipsychotic need to consider this and the related increased risk for weight related health problems.3 Making such decisions is complex and should include the patient because individual values will affect treatment acceptance. The results of the 18 month extension of this trial may be helpful and are expected shortly.

David M Gardner, PharmD
Dalhousie University
Halifax, Nova Scotia, Canada

The addition of olanzapine to valproate or lithium for acute manic or mixed bipolar episodes reduced manic symptoms

Evid Based Mental Health 2002 5: 89
doi: 10.1136/ebmh.5.3.89

Updated information and services can be found at:
http://ebmh.bmj.com/content/5/3/89

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://ebmh.bmj.com/content/5/3/89#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Bipolar disorder (236)
- Drugs: psychiatry (344)
- Clinical trials (epidemiology) (989)
- Epidemiology (1570)
- Neurology (1070)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/